2-Deoxy-D-glucose (also known as 2-DG) is an analog of glucose. It is a glycolytic inhibitor with antiviral activity. It has several potential indications, including as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors (lung, breast, pancreas, head, neck, and gastric tumors). It also has potential indications as an antiviral treatment in herpes simplex patients, and as an antiepileptic in temporal lobe epilepsy patients. 2-Deoxy-D-glucose (2-DG) is predominantly used as a diagnostic agent in its radiolabeled form (fluorine-18 is used as the radiolabel). Although there are several possible therapeutic indications for 2-DG, there is currently no approved indication for 2-DG as a therapeutic agent.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for 2-Deoxy-D-Glucose, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.